Dapagliflozin and empagliflozin cut mortality from heart failure with reduced ejection fraction whether or not patients have ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

Heart attacks are a leading cause of death and disability in Europe, and their effects often extend beyond the initial event, leading to chronic heart failure.

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

Heart failure - treatment ... Sodium-glucose transport protein 2 (SGLT2) inhibitors. In: StatPearls. StatPearls Publishing; 2024. Ferdinand KC, Elkayam U, Mancini D, et al. Use of isosorbide ...

SGLT-2 inhibitors include empagliflozin (Jardiance ... But, "you're still at high risk for stroke or heart failure, no matter what your A1c is," she stressed. "For SGLT-2s, I did not realize ...

From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular ejection fraction (LVEF) ...

Winters can be uncomfortable for many people, but they can prove life-threatening for those with hypertension if they don't ...